What PD Neurotechnology does

PD Neurotechnology is a London-headquartered medical device company founded in 2015 that develops PDMonitor, a CE-marked Class IIa wearable medical device ecosystem for continuous remote monitoring of Parkinson's disease symptoms. The system consists of five wearable sensors worn on the wrists and ankles, a SmartBox docking station, a mobile application, cloud-based storage, and a web-based physician tool. Kinematic data captured by the sensors is processed through proprietary machine learning algorithms developed over more than ten years of research at the University of Ioannina MedLab, enabling detection and quantification of nine motor symptoms including bradykinesia, dyskinesia, tremor, gait disturbances, freezing of gait, orthostatic instability, ON/OFF states, activity levels, and fluctuations. The company targets Parkinson's patients at any stage of disease, the neurologists and movement disorder specialists who treat them, and the caregivers who support daily disease management.

The business model combines direct-to-patient hardware sales with subscription-style access to the cloud platform and physician web tool. Patients purchase the PDMonitor system directly from PD Neurotechnology and are matched with a certified neurologist who monitors their data remotely. Neurologists must complete a structured certification program administered by the company before prescribing, creating a controlled clinical adoption pathway. International distribution is supported through channel partners such as Crimson International Investment, which serves as the exclusive distributor for Gulf countries. Pricing is not publicly disclosed, and insurance coverage is limited (potentially available through major German insurers but not yet broadly established). Operations are split across London (headquarters), Athens (sales and marketing), and Ioannina (R&D, production, distribution, and clinical studies), with R&D supported by a 60+ person academic lab at the University of Ioannina.

The company's research and regulatory footprint is substantial for its size. PDMonitor holds CE Class IIa certification under Directive 93/42/EEC, EU MDR 2017/745 compliance, EN ISO 13485:2016 quality certification, ISO 27001:2022 information security certification, Greek EOF registration, and a conditional NICE recommendation for NHS use in the UK. The company has published five peer-reviewed papers on PDMonitor in 2020 and continues active clinical validation work. Beyond the core PDMonitor product, PD Neurotechnology is developing HealthSonar (a non-invasive sleep and activity monitoring system using low-power radio waves) and the Smart Insole (a novel gait analysis wearable), and participates in the EU Horizon 2020-funded PD_Pal project for advanced Parkinson's care management. The company is privately held, with revenue not publicly disclosed, and remains pre-commercial at scale outside its core Greek and select European markets.

Name

PD Neurotechnology

Legal name

PD Neurotechnology Ltd

Website

https://pdneurotechnology.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

PD Neurotechnology is a London-based medical device company (founded 2015) that develops PDMonitor, a CE-marked Class IIa wearable system using proprietary machine learning to continuously monitor motor symptoms in Parkinson's disease patients for prescribing neurologists.

Ownership category

akta.pro rank

Product category

Wearable Medical Devices — Parkinson's Disease Monitoring

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Measuring & Controlling Devices, Nec (3829)

akta.pro primary industry

Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables) (HLAHACAE)

akta.pro secondary industry

Neurology RPM (epilepsy, Parkinson’s, MS monitoring) (HLALAFAJ)

Keywords

• Wearable medical devices
• Patient monitoring systems
• Parkinson's disease technology
• Movement disorder diagnostics
• Remote health monitoring

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices3 records

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. PDMonitor Device Sales: PD Neurotechnology sells PDMonitor as a medical device directly to patients. Patients purchase the system from the company and are matched with a certified healthcare professional who monitors their condition through the physician tool. The device includes hardware (wearable sensors, SmartBox) and access to the cloud platform and physician tool.
2. Cloud Platform and Software Services: Patients and physicians access the cloud platform and physician tool for continuous monitoring, data storage, and treatment decision support. Revenue is generated through the sale of the complete PDMonitor system which includes ongoing software and cloud services.
3. HealthSonar System: A new non-invasive monitoring system for sleep and healthy living using low power radio wave technologies. Part of the company's expanded product portfolio for health monitoring beyond Parkinson's disease.

Pricing tiers

Go-to-market motion3 records

Distribution channels3 records

Marketing channels7 records

Core offering

PD Neurotechnology develops and sells PDMonitor®, a CE-marked Class IIa medical device ecosystem that continuously monitors Parkinson's disease symptoms in patients' homes. The system consists of five wearable sensors (worn on wrists and ankles), a SmartBox docking station, a mobile application, cloud-based data storage, and a web-based Physician Tool for clinicians. Data is processed through proprietary algorithms and machine learning to objectively track nine motor symptoms and support remote treatment optimization by neurologists.

Product overview

PD Neurotechnology offers the PDMonitor® as its core product—an integrated medical device ecosystem for continuous remote monitoring of Parkinson's disease symptoms. The system comprises five wearable monitoring devices, a SmartBox connection station, a mobile application, cloud-based data storage, and a web-based Physician Tool. The company has also developed HealthSonar for sleep and daily activity monitoring, and participates in research projects including the Smart Insole (for gait analysis) and PD_Pal (European project for advanced Parkinson's care management).

Differentiator

Problem solved

Functional benefit

Products and services

• PDMonitor® A CE-marked Class IIa medical device ecosystem for continuous remote monitoring of Parkinson's disease patients. The system comprises five wearable sensors worn on different body parts (wrists and ankles), a SmartBox connection/docking station, a mobile application, cloud-based data storage, and a web-based Physician Tool. It tracks, records, and processes nine motor symptoms — bradykinesia, dyskinesia, tremor, gait disturbances, freezing of gait, orthostatic instability, ON/OFF states, activity, and fluctuations — and is used by patients at home in conjunction with a certified neurologist.

Quantifiable outcome

• Certified 30 neurologists from 6 countries (Germany, Italy, Sweden, Ireland, Greece, Cyprus) in PDMonitor usage within a single training initiative
• +2 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature5 records

Partnerships

Six partnerships are on record, tiered core and minor.

• Endeavor GreececoreStrategic or Co-development Partner · 11 January 2021PD Neurotechnology was selected among 9 companies for Endeavor's Scale-Up program, gaining access to strategic guidance from specialized mentors, funding through Endeavor's international investor network, and talent through cooperation with universities and companies internationally.
• PKNM Solutions SarlminorImplementation/ SI/ Consulting PartnerPKNM Solutions Sarl served as regulatory advisor throughout the CE certification process for PDMonitor, providing expertise on compliance with Medical Device Directive 93/42/EEC requirements.
• PD_Pal Project ConsortiumcoreStrategic or Co-development PartnerPD Neurotechnology participates in the PD_Pal project, a multi-center European project coordinated by University of Padua, developing innovative approaches to Parkinson's care using technology integration. The 4 million Euro EU Horizon 2020 funded project involves King's College London, University College London, University of Nijmegen, University of Ioannina, University of Marburg, and Paracelsus University Salzburg.
• HealthSonar Project ConsortiumcoreStrategic or Co-development PartnerPD Neurotechnology coordinates the HealthSonar project with partners including FORTH-IESL & ICS (Foundation of Research and Technology Hellas), NKUA (National Kapodistrian University of Athens), FORTH-IMBB, University of Patras, and Medis. The project develops a non-invasive system for monitoring sleep and healthy living using low power radio wave technologies.
• Smart Insole Project ConsortiumminorStrategic or Co-development PartnerPD Neurotechnology participates in the Smart Insole project developing a novel wearable sensor for continuous gait analysis using innovative materials and manufacturing methods. Funded under the Greek 'RESEARCH-CREATE-INNOVATE' program with European Regional Development Fund and national resources.
• Greek National Organization for Medicines (EOF)coreOthersPDMonitor is officially registered with the Greek National Organization for Medicines (EOF) with registration number 2820003711929, enabling legal sale as a medical product in the Greek market.

Scale indicators7 records

Recent moves8 records

Expansion highlights8 records

Direct peers

• Global Kinetics Corporation: Australian medical device company that developed the Personal KinetiGraph (PKG) wearable watch for objective, continuous measurement of Parkinson's disease motor symptoms. Direct competitor offering a similar wearable monitoring solution targeting neurologists and movement disorder specialists, with established commercial traction in multiple geographies.
• Great Lakes NeuroTechnologies: US-based company commercializing the Kinesia family of wearable sensors and software for quantitative assessment of Parkinson's disease motor symptoms. Direct competitor with FDA-cleared products, serving movement disorder clinics and clinical trials with similar kinematic-data-driven symptom monitoring.
• Cala Health: US medical device company developing wearable neurostimulation therapies (Cala Trio, Cala kIQ) for essential tremor and Parkinson's disease. Direct competitor in the wearable neurology space targeting the same Parkinson's patient population, though focused on therapeutic stimulation rather than monitoring.
• Charco Neurotech: UK-based startup developing the CUE1 wearable device for Parkinson's disease symptom relief through focused vibrotactile stimulation. Direct peer operating in the same wearable Parkinson's category from a UK base, targeting the same patient and specialist community with adjacent therapeutic wearable approach.

Emerging players

• Rune Labs: US digital health company offering StrivePD, an Apple Watch-based Parkinson's monitoring and care platform with FDA clearance and pharma partnerships. Emerging competitor leveraging consumer device distribution rather than proprietary hardware, which represents a different but overlapping approach to continuous Parkinson's symptom monitoring.
• Sensodiag: French medical device startup developing wearable sensors and AI algorithms for continuous monitoring of Parkinson's disease motor symptoms. Emerging European peer with overlapping wearable/ML approach to objective PD assessment, competing for similar clinical and research customers.

Broad incumbents

• Medtronic: Global medical device leader with deep involvement in Parkinson's disease through deep brain stimulation (DBS) systems and increasingly connected care/digital health platforms. Broad incumbent providing an alternative interventional treatment path and increasingly adjacent digital monitoring for PD patients.
• AbbVie: Global pharmaceutical leader in Parkinson's disease therapeutics (Duopa, Duodopa, Vyalev) and major funder of clinical research including digital biomarker programs. Broad incumbent representing both a competitor in adjacent digital PD solutions and a potential pharma-channel partner for clinical trial endpoints.
• Roche: Global pharmaceutical and diagnostics leader with growing investment in digital health, including the PD Digital Biomarker DREAM Challenge and partnerships around objective Parkinson's measurement. Broad incumbent operating at the intersection of diagnostics and digital biomarkers relevant to PD monitoring.

Others

• Michael J. Fox Foundation for Parkinson's Research: Major Parkinson's disease research foundation that funds digital biomarker development, wearable validation studies, and clinical consortia. Acts as an ecosystem participant rather than competitor — relevant because it influences payer validation, research collaborations, and clinical study design across the wearable PD monitoring space.

Market position

Strengths5 records

Weaknesses3 records

Competitive moat5 records

Key risks7 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/@PDNeurotechnology
• Facebookfacebook.com/pdneurotechnology

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds1 record

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PD Neurotechnology